Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

257.40SEK
21 Sep 2018
Change (% chg)

-12.10kr (-4.49%)
Prev Close
269.50kr
Open
270.00kr
Day's High
270.30kr
Day's Low
257.40kr
Volume
2,731,675
Avg. Vol
878,704
52-wk High
299.60kr
52-wk Low
107.40kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.68
Market Cap(Mil.): kr70,353.11
Shares Outstanding(Mil.): 273.32
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 36.98 30.48 32.69
EPS (TTM): 6.96 -- --
ROI: 21.09 13.04 12.72
ROE: 27.23 14.99 14.85

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

Jul 20 2018

Earnings vs. Estimates